Redo TAVR Superior to Explantation at 30 Days, Similar at 1 Year – Analysis of Medicare Patients
Repeat transcatheter aortic valve replacement (TAVR) procedures in high-risk patients showed an “acceptable” 30-day mortality rate, with short-term outcomes superior to those of surgical explantation of transcatheter heart valves but similar 1-year outcomes, according to a new analysis of Medicare patients.